Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NGM 707

Next Previous
Drug Profile

NGM 707

Alternative Names: NGM-707

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Leukocyte immunoglobulin-like receptor B1 antagonists; LILRB2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 06 Apr 2026 NGM Biopharmaceuticals withdraws a phase II trial in Solid tumours (Late-stage disease, Metastatic disease; Combination therapy) in due to sponsor's decision (NCT07511972)
  • 13 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase-I/IIb trial in Solid tumours presented at the60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 05 Apr 2024 Pharmacodynamics, efficacy, pharmacokinetic and adverse events data from the phase I/II in Solid tumor were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top